PSTX News and Press, Poseida Therapeutics Inc. From 08/11/22

Poseida Therapeutics press release ( NASDAQ: PSTX ): Q2 GAAP EPS of -$0.69 beats by $0.08 . Revenue of $2.7M beats by $1.77M . For further details see: Poseida Therapeutics GAAP EPS of -$0.69 beats by $0.08, revenue of $2.7M beats by $1.77M

Poseida Therapeutics Provides Updates and Financial Results for the Second Quarter of 2022 PR Newswire Announced strategic collaboration with Roche, with a $110 million upfront payment, to focus on the research and development of allogeneic CAR-T cell therapies dir...

Poseida Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares PR Newswire SAN DIEGO , Aug. 8, 2022 /PRNewswire/ -- Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-st...

Helius Medical Technologies ( HSDT ) -28% . Heart Test Laboratories ( HSCS ) -22% . Gannett ( GCI ) -20% on Q2 earnings release . Poseida Therapeutics ( PSTX ) -20% on pricing $70M stock offering . Kaspien Holdings ( KSPN ) ...

Poseida Therapeutics ( NASDAQ: PSTX ) shares plunged ~20% pre-market on Thursday after the biopharmaceutical company priced its underwritten public offering of 20M shares of its common stock at $3.50 per share. Gross proceeds are estimated to be ~$70M. In addition,...

Poseida Therapeutics Announces Pricing of Public Offering of Common Stock PR Newswire SAN DIEGO , Aug. 4, 2022 /PRNewswire/ -- Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage biopharmaceutical company utilizing proprietary genetic engineering ...

Poseida Therapeutics ( NASDAQ: PSTX ) shares slid ~13% during extended trading on Wednesday after the biopharmaceutical company proposed a public offering of common stock. Terms of the offering are yet to be determined. Poseida expects to grant the underwriters a 3...

Poseida Therapeutics Announces Proposed Public Offering of Common Stock PR Newswire SAN DIEGO , Aug. 3, 2022 /PRNewswire/ -- Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage biopharmaceutical company utilizing proprietary genetic engineering pl...

Poseida Therapeutics is developing P-BCMA-ALLO1 for multiple myeloma and P-MUC1C-ALLO1 for solid tumors; data readouts from both of these candidates are expected in the 2nd half of 2022. Poseida established a deal with Roche for allogeneic therapies targeting hematological malignancie...

Several biotechs involved in gene editing are higher on Wednesday in the aftermath of Roche's ( OTCQX:RHHBY ) blockbuster deal with CAR-T-focused Poseida Therapeutics ( PSTX ) announced earlier today. One of the biggest gainers -- up more than 30% -- is Alaunos The...